Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukemia and non-Hodgkin’s lymphoma: Dose-limiting myelosuppression without evidence of DNA hypomethylation

PURPOSE: Targeting aberrant DNA hypermethylation in chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL) with decitabine may reverse epigenetic silencing in B-cell malignancies. METHODS: Twenty patients were enrolled in two phase I trials to determine the minimum effective pharmacolog...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Blum, Kristie A., Liu, Zhongfa, Lucas, David M., Chen, Ping, Xie, Zhiliang, Baiocchi, Robert, Benson, Donald M., Devine, Steven M., Jones, Jeffrey, Andritsos, Leslie, Flynn, Joseph, Plass, Christoph, Marcucci, Guido, Chan, Kenneth K., Grever, Michael R., Byrd, John C.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2010
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917115/
https://ncbi.nlm.nih.gov/pubmed/20456354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2010.08213.x
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge